iRhythm (IRTC) Files Form 144 for 5,000-Share Sale on Nasdaq
Rhea-AI Filing Summary
iRhythm Technologies (IRTC) Form 144 reports a proposed sale of 5,000 common shares to occur on 09/03/2025 through Morgan Stanley Smith Barney LLC on Nasdaq with an aggregate market value of $875,000. The filing shows the 5,000 shares were originally granted as restricted stock in four tranches between 07/01/2020 and 12/31/2023, and the total equals the 5,000 shares listed for sale. The filer previously sold 3,737 shares in the past three months for aggregate proceeds of $573,285.36. The filing includes the required attestation that the seller is not aware of undisclosed material adverse information.
Positive
- Full disclosure of share origin: The filing lists acquisition dates and amounts that exactly match the 5,000 shares proposed for sale.
- Broker and exchange specified: Morgan Stanley Smith Barney LLC and Nasdaq are named, which clarifies execution venue.
- Compliance attestation included: The filer represents no undisclosed material adverse information, meeting Rule 144 requirements.
Negative
- None.
Insights
TL;DR: Routine insider sale filing showing planned disposition of restricted shares through a broker; size is immaterial to market cap.
The Form 144 documents a routine notice of proposed sale by an insider or affiliate, using Morgan Stanley Smith Barney LLC as broker on Nasdaq. The 5,000-share block equals the aggregate of four restricted-stock issuances listed in the filing, indicating the sale is of vested/issued shares rather than a secondary transfer from a third party. Recent dispositions of 737 and 3,000 shares in June and September 2025 are disclosed, with combined recent proceeds of $573,285.36. Given the company's outstanding shares of 32,127,763, the proposed sale represents roughly 0.016% of shares outstanding, which is unlikely to be material to valuation but is relevant for transparency and insider activity tracking.
TL;DR: Filing reflects compliance with Rule 144 disclosure; it documents source and timing of restricted-stock acquisitions.
The notice clearly ties the securities to specific restricted-stock grants dated 2020, 2022, 2023, and 2023, listing acquisition dates and quantities that sum to the 5,000 shares to be sold. This level of granularity supports compliance with Rule 144 aggregation and attestation requirements. The included representation regarding lack of undisclosed material information and mention of trading-plan related fields (left blank) indicate no reliance disclosed on a Rule 10b5-1 plan within this filing. For governance monitoring, the filing provides the necessary facts without revealing additional company-sensitive information.